• 1
    Ghobrial MW, George J, Mannam S, Henien SR. Severe hypercalcemia as an initial presenting manifestation of hepatocellular carcinoma. Can J Gastroenterol. 2002; 16: 607609.
  • 2
    Aklilu F, Park M, Goltzman D, Rabbani SA. Increased PTHRP production by a tyrosine kinase oncogene, Tpr-Met: role of the Ras signaling pathway. Am J Physiol. 1996; 271: E277E283.
  • 3
    Tfelt-Hansen J, MacLeod RJ, Chattopadhyay N, et al. Calcium-sensing receptor stimulates PTHrP release by pathways dependent on PKC, p38 MAPK, JNK, and ERK1/2 in H-500 cells. Am J Physiol Endocrinol Metab. 2003; 285: E329E337.
  • 4
    Suva LJ, Winslow GA, Wettenhall RE, et al. A parathyroid hormone-related protein implicated in malignant hypercalcemia: cloning and expression. Science. 1987; 237: 893896.
  • 5
    Barbier JR, MacLean S, Morley P, Whitfield JF, Willick GE. Structure and activities of constrained analogues of human parathyroid hormone and parathyroid hormone-related peptide: implications for receptor-activating conformations of the hormones. Biochemistry. 2000; 39: 1452214530.
  • 6
    de Miguel F, Fiaschi-Taesch N, Lopez-Talavera JC, et al. The C-terminal region of PTHrP, in addition to the nuclear localization signal, is essential for the intracrine stimulation of proliferation in vascular smooth muscle cells. Endocrinology. 2001; 142: 40964105.
  • 7
    Esbrit P, Alvarez-Arroyo MV, de Miguel F, Martin O, Martinez ME, Caramelo C. C-terminal parathyroid hormone-related protein increases vascular endothelial growth factor in human osteoblastic cells. J Am Soc Nephrol. 2000; 11: 10851092.
  • 8
    Cormier S, Delezoide AL, Silve C. Expression patterns of parathyroid hormone-related peptide (PTHrP) and parathyroid hormone receptor type 1 (PTHR1) during human development are suggestive of roles specific for each gene that are not mediated through the PTHrP/PTHR1 paracrine signaling pathway. Gene Expr Patterns. 2003; 3: 5963.
  • 9
    Guise TA, Yin JJ, Thomas RJ, Dallas M, Cui Y, Gillespie MT. Parathyroid hormone-related protein (PTHrP)-(1-139) isoform is efficiently secreted in vitro and enhances breast cancer metastasis to bone in vivo. Bone. 2002; 30: 670676.
  • 10
    Gallwitz WE, Guise TA, Mundy GR. Guanosine nucleotides inhibit different syndromes of PTHrP excess caused by human cancers in vivo. J Clin Invest. 2002; 110: 15591572.
  • 11
    Zhao Q, Brauer PR, Xiao L, McGuire MH, Yee JA. Expression of parathyroid hormone-related peptide (PthrP) and its receptor (PTH1R) during the histogenesis of cartilage and bone in the chicken mandibular process. J Anat. 2002; 201: 137151.
  • 12
    Naito S, Shimizu K, Akino K, et al. Autocrine/paracrine involvement of parathyroid hormone-related peptide in vascular leiomyoma. Endocr J. 2002; 49: 335341.
  • 13
    Blackshaw LA. Parathyroid hormone-related peptide: a jack of all trades that masters gastric responses to stress. J Gastroenterol Hepatol. 2003; 18: 13.
  • 14
    Kageshita T, Ishihara T, Tokuo H, et al. Widespread expression of parathyroid hormone-related peptide in melanocytic cells. Br J Dermatol. 2003; 148: 533538.
  • 15
    Chattopadhyay N, Evliyaoglu C, Heese O, et al. Regulation of secretion of PTHrP by Ca2+-sensing receptor in human astrocytes, astrocytomas, and meningiomas. Am J Physiol Cell Physiol. 2000; 279: C691C699.
  • 16
    Nakamura M, Hashimoto T, Furuyama J, Kakudo K. Multiple alternative splice isoforms of parathyroid hormone-related peptide mRNA in human cell lines. J Mol Endocrinol. 1995; 15: 245249.
  • 17
    Sidler B, Alpert L, Henderson JE, et al. Amplification of the parathyroid hormone-related peptide gene in a colonic carcinoma. J Clin Endocrinol Metab. 1996; 81: 28412847.
  • 18
    Ito M, Nakashima M, Alipov GK, et al. Gastric cancer associated with overexpression of parathyroid hormone-related peptide (PTHrP) and PTH/PTHrP receptor in relation to tumor progression. J Gastroenterol. 1997; 32: 396400.
  • 19
    Nakashima M, Ohtsuru A, Luo WT, et al. Expression of parathyroid hormone-related peptide in human thyroid tumours. J Pathol. 1995; 175: 227236.
  • 20
    Akino K, Ohtsuru A, Yano H, et al. Antisense inhibition of parathyroid hormone-related peptide gene expression reduces malignant pituitary tumor progression and metastases in the rat. Cancer Res. 1996; 56: 7786.
  • 21
    Surowiak P, Dziegiel P, Matkowski R, et al. Prognostic value of immunocytochemical determination of parathyroid hormone-related peptide expression in cells of mammary ductal carcinoma. Analysis of 7 years of the disease course. Virchows Arch. 2003; 442: 245251.
  • 22
    Ebinuma H, Imaeda H, Fukuda Y, et al. A case of parathyroid hormone-related peptide producing gallbladder carcinoma and establishment of a cell line, PTHrP-GBK. Dig Dis Sci. 2002; 47: 125129.
  • 23
    Li H, Seitz PK, Selvanayagam P, Rajaraman S, Cooper CW. Effect of endogenously produced parathyroid hormone-related peptide on growth of a human hepatoma cell line (Hep G2). Endocrinology. 1996; 137: 23672374.
  • 24
    Sunardhi-Widyaputra S, Van Damme B. Parathyroid hormone-related peptide: immunolocalisation in normal salivary glands and in pleomorphic adenomas. Pathol Res Pract. 1996; 192: 1519.
  • 25
    Chattopadhyay N, Brown EM. Retinoic acid receptors are expressed in human primary astrocytes and their agonists inhibit parathyroid hormone-related peptide expression and secretion. Brain Res Mol Brain Res. 2001; 92: 172176.
  • 26
    Evliyaoglu C, Carroll R, Folkerth R, Bello L, Bruns DE, Black PM. Parathyroid hormone-related protein and its receptor in human glial tumors. Acta Neurochir (Wien). 2000; 142: 871878.
  • 27
    Brines ML, Ling Z, Broadus AE. Parathyroid hormone-related protein protects against kainic acid excitotoxicity in rat cerebellar granule cells by regulating L-type channel calcium flux. Neurosci Lett. 1999; 274: 1316.
  • 28
    de Miguel F, Sarasa JL, Lopez-Ferro O, Esbrit P. Immunohistochemical detection of parathyroid hormone-related protein in human astrocytomas. J Histochem Cytochem. 1998; 46: 277279.
  • 29
    Akino K, Ohtsuru A, Kanda K, et al. Parathyroid hormone-related peptide is a potent tumor angiogenic factor. Endocrinology. 2000; 141: 43134316.
  • 30
    Aklilu F, Gladu J, Goltzman D, Rabbani SA. Role of mitogen-activated protein kinases in the induction of parathyroid hormone-related peptide. Cancer Res. 2000; 60: 17531760.
  • 31
    Amizuka N, Ozawa H, Sasaki T. The biological action of parathyroid hormone-related peptide (PTHrP) and fibroblast growth factor receptor 3 (FGFR3) on bone and cartilage. Kaibogaku Zasshi. 2000; 75: 415425.
  • 32
    Karperien M, Farih-Sips H, Lowik CW, de Laat SW, Boonstra J, Defize LH. Expression of the parathyroid hormone-related peptide gene in retinoic acid-induced differentiation: involvement of ETS and Sp1. Mol Endocrinol. 1997; 11: 14351448.
  • 33
    Miao D, Tong XK, Chan GK, Panda D, McPherson PS, Goltzman D. Parathyroid hormone-related peptide stimulates osteogenic cell proliferation through protein kinase C activation of the Ras/mitogen-activated protein kinase signaling pathway. J Biol Chem. 2001; 276: 3220432213.
  • 34
    Zuscik MJ, Pateder DB, Puzas JE, Schwarz EM, Rosier RN, O'Keefe RJ. Lead alters parathyroid hormone-related peptide and transforming growth factor-β1 effects and AP-1 and NF-κB signaling in chondrocytes. J Orthop Res. 2002; 20: 811818.
  • 35
    Bakker B, van der Eerden BC, Koppenaal DW, Karperien M, Wit JM. Effect of X-irradiation on growth and the expression of parathyroid hormone-related peptide and Indian hedgehog in the tibial growth plate of the rat. Horm Res. 2003; 59: 3541.
  • 36
    Daumas-Duport C, Scheithauer B, O'Fallon J, Kelly P. Grading of astrocytomas. A simple and reproducible method. Cancer. 1998; 62: 21522165.
  • 37
    Radner H, Blumcke I, Reifenberger G, Wiestler OD. [The new WHO classification of tumors of the nervous system 2000. Pathology and genetics]. Pathologe. 2002; 23: 260283.
  • 38
    Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53: 457481.
  • 39
    Shankar PP, Wei H, Davee SM, Funk JL. Parathyroid hormone-related protein is expressed by transformed and fetal human astrocytes and inhibits cell proliferation. Brain Res. 2000; 868: 230240.
  • 40
    Holt EH, Broadus AE, Brines ML. Parathyroid hormone-related peptide is produced by cultured cerebellar granule cells in response to L-type voltage-sensitive Ca2+ channel flux via a Ca2+/calmodulin-dependent kinase pathway. J Biol Chem. 1996; 271: 2810528111.
  • 41
    Vito P, Lacana E, D'Adamio L. Interfering with apoptosis: Ca2+-binding protein ALG-2 and Alzheimer's disease gene ALG-3. Science. 1996; 271: 521525.
  • 42
    Chatterjee O, Nakchbandi IA, Philbrick WM, et al. Endogenous parathyroid hormone-related protein functions as a neuroprotective agent. Brain Res. 2002; 930: 5866.
  • 43
    Funk JL, Trout CR, Wei H, Stafford G, Reichlin S. Parathyroid hormone-related protein (PTHrP) induction in reactive astrocytes following brain injury: a possible mediator of CNS inflammation. Brain Res. 2001; 915: 195209.
  • 44
    Serra R, Karaplis A, Sohn P. Parathyroid hormone-related peptide (PTHrP)-dependent and -independent effects of transforming growth factor β (TGF-β) on endochondral bone formation. J Cell Biol. 1999; 145: 783794.
  • 45
    Motokura T, Endo K, Kumaki K, Ogata E, Ikeda K. Neoplastic transformation of normal rat embryo fibroblasts by a mutated p53 and an activated ras oncogene induces parathyroid hormone-related peptide gene expression and causes hypercalcemia in nude mice. J Biol Chem. 1995; 270: 3085730861.
  • 46
    Cryns VL, Thor A, Xu HJ, et al. Loss of the retinoblastoma tumor-suppressor gene in parathyroid carcinoma. N Engl J Med. 1994; 330: 757761.
  • 47
    Kraus JA, Bolin C, Wolf HK, et al. TP53 alterations and clinical outcome in low grade astrocytomas. Genes Chromosomes Cancer. 1994; 10: 143149.
  • 48
    Korkolopoulou P, Kouzelis K, Christodoulou P, Papanikolaou A, Thomas-Tsagli E. Expression of retinoblastoma gene product and p21 (WAF1/Cip 1) protein in gliomas: correlations with proliferation markers, p53 expression and survival. Acta Neuropathol (Berl). 1998; 95: 617624.
  • 49
    van Meyel DJ, Ramsay DA, Casson AG, Keeney M, Chambers AF, Cairncross JG. p53 mutation, expression, and DNA ploidy in evolving gliomas: evidence for two pathways of progression. J Natl Cancer Inst. 1994; 86: 10111017.
  • 50
    Aklilu F, Park M, Goltzman D, Rabbani SA. Induction of parathyroid hormone-related peptide by the Ras oncogene: role of Ras farnesylation inhibitors as potential therapeutic agents for hypercalcemia of malignancy. Cancer Res. 1997; 57: 45174522.
  • 51
    Fortino V, Torricelli C, Gardi C, Valacchi G, Rossi PS, Maioli E. ERKs are the point of divergence of PKA and PKC activation by PTHrP in human skin fibroblasts. Cell Mol Life Sci. 2002; 59: 21652171.
  • 52
    Yamanaka Y, Tanaka H, Koike M, Nishimura R, Seino Y. PTHrP rescues ATDC5 cells from apoptosis induced by FGF receptor 3 mutation. J Bone Miner Res. 2003; 18: 13951403.